Mark L. Hayman, Ph.D.

Mark is well versed in building patent portfolios to optimize product exclusivity positions for a wide array of technologies, including protein and peptide therapeutics; metabolic engineering and enzyme engineering; microbiome-related diagnostics and therapeutics; nucleic acid-based therapeutics; diagnostic and prognostic tests, including genetic, gene expression, proteomic and cell-based tests for personalized medicine applications; bioinformatics; nucleic acid sequencing and detection technologies; recombinant protein production; nanoparticle-based drug delivery platforms; and wound care technologies.

Mark co-authored several publications in peer-reviewed journals, including the Journal of Biological Chemistry, Nucleic Acids Research, Infection and Immunity, and Nature Biotechnology. Prior to joining Morgan Lewis, Mark was a partner in the corporate practice group of another international law firm.